Company Updates covers news from Brilliant Blue Biosciences. Research & Industry News highlights relevant developments published by external sources, summarised and attributed to them.
Sensible Biotechnologies raised $47 million to scale VECTOR, its integrated platform pairing AI-enabled mRNA design with manufacturing of naturally modified mRNA in living cells, aiming to develop novel therapeutics beyond vaccines.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Three scientists have won this year’s Nobel Prize in medicine for developing optogenetics, a technology that uses light to control nerve signals. While their work has been mostly used in research, the method has birthed ...
Source: Endpoints News
Read more →The Nobel Prize committee says that optogenetics will lay the foundations for a new era in neuroscience, as pharma explores its role on treating ophthalmic conditions.
Source: Pharmaceutical Technology
Read more →Sensible Biotechnologies is looking to mark its territory in the increasingly hot space of mRNA therapeutics, raising $47 million in a Series A round to develop its manufacturing approach. “Current mRNA technology is fine for ...
Source: Endpoints News
Read more →Gene-editing CRISPR enzymes controlled by light and sound target tissues of interest.
Source: Nature
Read more →From vaccines to gene therapies, mRNA medicines often rely on tiny fat-based particles called lipid nanoparticles, or LNPs, to carry treatments where they need to go. But researchers still face a fundamental challenge: getting those therapies to the organs where they are needed most while limiting side effects elsewhere in the body.
Source: Phys.org
Read more →Dr. Kevin Kemp and his research team at the University of Bristol have converted the high-risk Alzheimer's gene APOE4 into the lower-risk APOE3 gene.
Source: Medical Xpress
Read more →RNA vaccines and other nucleic acid therapeutics are typically packaged within fatty molecules known as lipid nanoparticles (LNPs). MIT researchers have now developed a way to produce these particles much more quickly and with more precise control over their size and shape.
Source: Phys.org
Read more →Researchers at The University of Texas at Austin have teamed up with pharmaceutical company Eli Lilly and Company to uncover how storage conditions affect mRNA lipid nanoparticles (LNPs), the technology behind COVID-19 vaccines and other treatments, and how to make them more effective.
Source: Phys.org
Read more →MIT News reports a two-stage process that measures lipid nanoparticle size during production and uses the resulting data to guide processing conditions for RNA-therapy development. The team is pursuing commercialisation through BIZON Labs; no clinical testing is reported.
Source: MIT News
Read more →Researchers have engineered a drug treatment that shows rapid effectiveness against endometriosis in early testing, laying the foundation for a potential therapy for an incurable, chronic disease that affects 1 in 10 women. The targeted nanotherapy, developed by a team of scientists at Washington State University, reduced endometriosis symptoms and disease progression after a single dose in a mouse model.
Source: Phys.org
Read more →GBI plans to introduce SmartScale, a service aimed at early-stage developers seeking GMP material for clinical development. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
